



Akerman LLP
Las Olas Centre II, Suite 1600
350 East Las Olas Boulevard
Fort Lauderdale, FL 33301-2999
Tel: 954.463.2700
Fax: 954.463.2224

September 11, 2014

Securities and Exchange Commission
Division of Corporation Finance
Attn: Jeffrey P. Riedler, Assistant Director
100 F. Street, N.E.
Washington, DC 20549

**Re: Catalyst Pharmaceutical Partners, Inc.
Form 10-K for the Fiscal year Ended December 31, 2013
Filed March 19, 2014
File No. 001-33057**

Dear Mr. Riedler:

We are responding to a question presented in a telephonic conversation, dated September 5, 2014, between Andrew Schwartz of this office and Bryan Pitko of your office.

- **Please inform the Commission as to when the Company expects it will include information regarding the royalties to be paid pursuant to the License Agreement.**

The Company expects that it will begin including this information in its filings with the Commission beginning with its Annual Report on Form 10-K for the fiscal year ending December 31, 2014.

We look forward to hearing back from you regarding this response. If you have any questions, please feel free to give me a call.

Sincerely,

/s/ Philip B. Schwartz

Philip B. Schwartz

akerman.com